SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and tests of key support levels dominate discussion, with many traders fearing further downside while others argue the market is oversold and see a potential bottom. Traders also point to ETF outflows, macroeconomic pressure, and exchange-security concerns as possible headwinds, but no single explanation is clearly established.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline alongside a broader crypto-market selloff has put the psychologically important $1 level in focus, with traders watching for a break and citing weak risk appetite and leveraged liquidations. The community is split between expecting further losses and treating the dip as an opportunity to accumulate.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the FDAs PDUFA decision on ivonescimab for EGFR-mutated lung cancer, with traders treating the outcome as a high-stakes binary event. The debate centers on the drugs strong progression-free-survival results and favorable but not statistically significant overall-survival data versus the FDAs stated need for significant survival evidence, leaving approval, a delay, or a rejection in question.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immixs NXC-201 CAR-T results in relapsed/refractory AL amyloidosis, including new ASH presentation data, are driving attention, with bullish traders emphasizing responses and safety as support for a future BLA. The optimism is tempered by concerns over financing dilution, a longer regulatory timeline, and weak biotech sentiment, while traders also debate short interest and the stocks decline.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile pullback after a major prior rally, amid broader crypto weakness and reports of leveraged liquidations. Traders are split between calling the decline an oversold buying opportunity and expecting further losses, with many questioning whether ZEC can regain support.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 9.8476659 USD and is down -2.55 over the last 24 hours. It is currently trading on 2316 active market(s) with $307,298,586.51 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention amid a volatile rally and renewed breakout talk, with traders citing Chainlinks role in tokenized-stock infrastructure and institutional adoption as bullish drivers. Others argue that partnerships and usage have not translated into lasting token gains, pointing to pullbacks and weak performance.

Pinterest, Inc. engages in the operation of an AI-powered visual search and discovery platform. It enables users to find inspiration, curate ideas, search for products, and discover content through visual recommendations. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is under pressure after Q3 results missed revenue expectations and its softer Q4 outlook prompted analyst target cuts, despite record user growth. Traders debate whether its growing audience and AI-powered shopping and ad products can drive stronger monetization, while skeptics question ad pricing and whether browsing converts to purchases.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP ETF inflows, regulatory-clarity speculation and institutional-adoption hopes are driving discussion around the Bitwise fund, alongside sharp swings in XRP and broader crypto markets. Bulls view the flows and potential policy progress as supportive, while skeptics question whether those developments will translate into sustained gains and point to recent weakness.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMAs stronger-than-expected Q3 results, led by accelerating ASCENIV growth and a higher earnings outlook, drove a sharp share-price rebound and renewed bullish discussion. Traders are debating whether the growth can sustain a broader rerating, while some point to lingering skepticism and weak follow-through; buyout talk remains speculation.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,704,555,155.77490568 with 589,238,111,425,239.3151592 in circulation. The last known price of Shiba Inu is 0.00000425 USD and is down -2.37 over the last 24 hours. It is currently trading on 1128 active market(s) with $56,784,935.49 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention amid a prolonged, choppy decline, with repeated chart commentary describing bearish structure and consolidation. Holders are split between hoping for a meme-coin rebound and expressing frustration over weak performance, limited utility, and stalled token burns.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Do Options Traders Know Something About UHS Stock We Don't?

Investors need to pay close attention to Universal Health Services stock based on the movements in the options market lately.

UHS Misses Q3 Earnings Estimates Despite Higher Patient Volumes

Universal Health Services' Q3 earnings fall 8.3% despite revenue growth, as rising costs and Acute Care pricing pressure offset higher patient volumes.

Compared to Estimates, Universal Health Services (UHS) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Universal Health Services (UHS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Universal Health Services (UHS) Misses Q3 Earnings Estimates

Universal Health Services (UHS) delivered earnings and revenue surprises of -1.70% and +0.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?

Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.

Analysts Estimate Universal Health Services (UHS) to Report a Decline in Earnings: What to Look Out for

Universal Health Services (UHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare's stronger cash flow is fueling bigger buybacks, but growth investments and capital needs will test how sustainable its strategy is.

Implied Volatility Surging for Universal Health Services Stock Options

Investors need to pay close attention to UHS stock based on the movements in the options market lately. 

Can Shorter Hospital Stays Help HCA Handle More Patient Demand?

HCA's rising admissions and shorter hospital stays could help it meet growing patient demand while using existing capacity more efficiently.

Can Tenet Healthcare Sustain Growth Despite Lower Surgical Volumes?

THC's revenue growth persists despite softer surgical volumes, driven by higher revenue per case, acuity and favorable service mix.

• Reported GAAP EPS of $5.22 down -8.26% YoY
• Reported revenue of $4.73B up 5.30% YoY

Universal Health Services' Q3 earnings and adjusted EBITDA were below Q3 2025; acute-care revenue per adjusted admission and patient day declined, while Medicaid policy changes may reduce revenue and increase uncompensated care.

Universal Health Services reported higher Q3 revenue, behavioral-health same-facility revenue, admissions and revenue per adjusted admission, and nine-month operating cash flow compared with corresponding 2025 periods.

Universal Health Services, Inc. engages in providing hospital and healthcare services. It operates through the following segments: Acute Care Hospital Services, Behavioral Health Care Services, and Other. The Acute Care Hospital Services segment includes hospitals, freestanding emergency departments, and ambulatory centers. The Behavioral Health Care Services segment offers treatment programs for depression, anxiety, psychotic diagnoses, bipolar disorder, post-traumatic stress disorder, and neurorehabilitation. The Other segment consists of centralized services such as information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising, and design and construction. The company was founded by Alan B. Miller in 1979 and is headquartered in King of Prussia, PA.

Universal Health Services, Inc. - Ordinary Shares - Class B

Bearish Sentiment

<ul class="summary-bullets"><li>Deutsche Bank upgraded Teladoc to Buy from Hold and set a price target of $11, more than double Monday’s closing price.</li><li>Deutsche Bank noted a “potential exit scenario” for Teledoc Health after Talkspace was acquired by Universal Health.</li><li>UHS’ Talkspace acquisition is “a clear positive for Teladoc,” said BoFA.</li></ul>Teladoc Health (TDOC) drew investor interest on Tuesday, with its shares surging more than 10% in pre-market trading, following a couple of bullish brokerage actions, citing the stock’s “compelling” valuation.If the pre-market levels hold, <a href="https://stocktwits.com/symbol/TDOC">TDOC stock</a> could open at its highest price since Jan. 26, 2026.The company caught brokerages’ attention after its peer <a href="https://stocktwits.com/symbol/TALK">Talkspace (TALK)</a> signed a deal to be acquired by <a href="https://stocktwits.com/symbol/UHS">Universal Health Services (UHS)</a> for $5.25 per share, or about $835 million, on Monday. The transaction is expected to close in the third quarter of 2026.<h2 class="st-heading-2">Analyst Highlights “Potential Exit Scenario” For Teladoc</h2>Deutsche Bank upgraded Teladoc to ‘Buy’ from ‘Hold’ and set a price target of $11, according to&nbsp;The Fly. This represents a 107% upside from the stock’s closing price of $5.3 on Monday.The brokerage said Teladoc’s valuation looks “compelling” at current levels and believes the company has a “deliverable strategy” for BetterHelp, its online therapy platform. Deutsche Bank also noted a “potential exit scenario”, pointing to a comparable transaction that could serve as a roadmap for the company.While BetterHelp has recently faced declining growth, the firm believes Teladoc’s integrated care segment continues to expand, and management has a long-term plan to stabilize and return BetterHelp to growth, the firm added.Meanwhile, BofA raised its price target on Teladoc to $8.25 from $7 and maintained a ‘Buy’ rating. UHS’ Talkspace acquisition is “a clear positive for Teladoc” that provides “further support that the market is undervaluing Teladoc's virtual therapy business as well as the rest of Teladoc,” it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits shifted to “bullish” from “bearish” over the past 24 hours.<img src="https://news.stocktwits-cdn.com/TDOC_jpg_10651f7b4a.webp" alt="TDOC.jpg">Chatter was largely bullish, with one user saying the company would be worth over $200 billion.<stembedurl>https://stocktwits.com/trplbiem/message/647086931</stembedurl>Another user said, “Teledoc is better equipped than any of their competitors.”<stembedurl>https://stocktwits.com/Idonno/message/647090994</stembedurl>Year-to-date, the stock has declined around 17%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-inkt-stock-surge-in-pre-market-today/cZdoFYVRIeu">Why Did INKT Stock Surge 70% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Teladoc logo is seen on a smartphone screen and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

TDOC Stock Surges 10% Pre-Market, Analyst Cites ‘Compelling’ Valuation After Talkspace Deal

Teladoc Health drew investor interest following a couple of bullish brokerage actions after peer Talkspace signed an acquisition agreement with Universal Health Services a day earlier.

TDOC Stock Surges 10% Pre-Market: Wall Street Sees ‘Compelling’ Valuation, Retail Traders Shift Tone

Equity

ARK Innovation ETF

Talkspace Inc

Teladoc Health Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$5.63	--	--	N/A
Q3 '26	$5.19	$5.22	0.54%	BEAT
Q2 '26	$5.94	$5.98	0.67%	BEAT
Q1 '26	$5.41	$5.62	3.91%	BEAT
Q4 '25	$5.86	$5.88	0.35%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

UHS Earnings

Latest Earnings Results: Q3 '26

Historical Earnings